Cancer treatment news
The latest clinical trial results, drug approvals and major scientific events, with sources cited.
Exercise as treatment: a 3-year exercise programme cut the risk of bowel cancer coming back by 28%
A regular 3-year exercise programme after chemotherapy for bowel cancer meant the disease came back less often and patients lived longer.
Head and neck cancer: the first immunotherapy before and after surgery, after two decades
Adding immunotherapy before and after surgery in advanced head and neck cancer kept more patients free of the cancer coming back for up to 3 years; the first advance in this treatment in two decades.
Low-dose aspirin halved bowel cancer recurrence in patients with PI3K mutations
In people with bowel cancer whose tumour had a particular genetic change, one low-dose aspirin tablet a day after treatment almost halved the chance of the disease coming back.
Targeted lutetium-PSMA radiation treatment reaches an earlier stage of prostate cancer
A treatment that carries a radioactive substance straight to prostate cancer cells has now, together with hormone therapy, also kept the disease under control for longer at an earlier stage of cancer that has spread.
Hormone-positive breast cancer: an all-oral giredestrant + everolimus regimen delayed progression
In advanced hormone-positive breast cancer that had grown after earlier treatment, a combination of two tablets kept the disease under control almost twice as long, especially when the tumour had an ESR1 genetic change.
Stomach cancer: immunotherapy around surgery now also improves overall survival
Adding an immunotherapy drug to chemotherapy before and after surgery for stomach cancer helped patients live longer.
First CAR-T cell therapy approved for a solid tumour: satri-cel in stomach cancer
The patient's own immune cells are changed so that they attack stomach cancer cells; this is the first CAR-T cell therapy for a solid cancer, and it has been approved in China.
Daraxonrasib: the first anti-RAS drug to double survival in pancreatic cancer
In advanced pancreatic cancer that had already been treated, daraxonrasib tablets almost doubled how long patients lived, and the drug has been approved in the United States.
Ivonescimab: a dual-action antibody helped people with lung cancer live longer
A new antibody that hits two targets at once, given with chemotherapy for advanced lung cancer, helped patients live longer than a widely used immunotherapy.
Multiple myeloma: teclistamab plus daratumumab cut the risk of progression by 83%
In myeloma that has come back, a combination of two antibody drugs kept the disease under control in about 8 in every 10 patients for up to 3 years; with the usual treatment, in only 3.